Salud financiera de hoja de balance de EQL Pharma
Salud financiera controles de criterios 3/6
EQL Pharma tiene un patrimonio de accionistas total de SEK197.9M y una deuda total de SEK148.2M, lo que sitúa su ratio deuda-patrimonio en 74.9%. Sus activos y pasivos totales son SEK423.3M y SEK225.4M respectivamente. El BAIT de EQL Pharma es de SEK47.7M, por lo que su ratio de cobertura de intereses es de 5.9. Tiene efectivo e inversiones a corto plazo que ascienden a SEK11.8M.
Información clave
74.9%
Ratio deuda-patrimonio
SEK 148.22m
Deuda
| Ratio de cobertura de intereses | 5.9x |
| Efectivo | SEK 11.83m |
| Patrimonio | SEK 197.89m |
| Total pasivo | SEK 225.41m |
| Activos totales | SEK 423.30m |
Actualizaciones recientes sobre salud financiera
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12
Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29Recent updates
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?
Nov 27Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
Oct 29EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (SEK232.7M) de EQL superan a sus pasivos a corto plazo (SEK186.9M).
Pasivo a largo plazo: Los activos a corto plazo de EQL (SEK232.7M) superan a sus pasivos a largo plazo (SEK38.5M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de EQL (68.9%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de EQL ha crecido de 0% a 74.9% en los últimos 5 años.
Cobertura de la deuda: El flujo de caja operativo de EQL es negativo, por lo que la deuda no está bien cubierta.
Cobertura de intereses: Los pagos de intereses de la deuda de EQL están bien cubiertos por el BAIT (5.9x cobertura).